398 756

Cited 20 times in

Combined effects of niclosamide and temozolomide against human glioblastoma tumorspheres

DC Field Value Language
dc.contributor.author강석구-
dc.contributor.author김남희-
dc.contributor.author김의현-
dc.contributor.author김현실-
dc.contributor.author문주형-
dc.contributor.author육종인-
dc.contributor.author장종희-
dc.date.accessioned2020-12-01T17:11:51Z-
dc.date.available2020-12-01T17:11:51Z-
dc.date.issued2020-11-
dc.identifier.issn0171-5216-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/180163-
dc.description.abstractPurpose: Glioblastoma (GBM) is the most aggressive type of brain tumor and has poor survival outcomes, even after a combination of surgery, radiotherapy, and chemotherapy. Temozolomide is the only agent that has been shown to be effective against GBM, suggesting that combination of temozolomide with other agents may be more effective. Niclosamide, an FDA approved anthelmintic agent, has shown anti-cancer effects against human colon, breast, prostate cancers as well as GBM. However, the efficacy of the combination of niclosamide with temozolomide against GBM tumorspheres (TSs) has not been determined. We hypothesized that the combined treatment could effectively suppress GBM TSs. Methods: GBM TSs (TS15-88, GSC11) were treated with niclosamide and/or temozolomide. Combined effects of two drugs were evaluated by measuring viability, neurosphere formation, and 3D-invasion in collagen matrix. Transcriptional profiles of GBM TS were analyzed using RNA sequencing. In vivo anticancer efficacy of combined drugs was tested in a mouse orthotopic xenograft model. Results: Combination treatment of niclosamide and temozolomide significantly inhibited the cell viability, stemness, and invasive properties of GBM TSs. This combined treatment significantly down-regulated the expression of epithelial mesenchymal transition-related markers, Zeb1, N-cadherin, and β-catenin. The combined treatment also significantly decreased tumor growth in orthotopic xenograft models. Conclusion: The combination of niclosamide and temozolomide effectively decreased the stemness and invasive properties of GBM TSs, suggesting that this regimen may be therapeutically effective in treating patients with GBM.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish, German-
dc.publisherSpringer-Verlag-
dc.relation.isPartOfJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAnimals-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols / pharmacology*-
dc.subject.MESHBrain Neoplasms / pathology*-
dc.subject.MESHCell Line, Tumor-
dc.subject.MESHCell Survival / drug effects-
dc.subject.MESHEpithelial-Mesenchymal Transition / drug effects-
dc.subject.MESHGlioblastoma / pathology*-
dc.subject.MESHHumans-
dc.subject.MESHMice-
dc.subject.MESHNeoplastic Stem Cells / drug effects-
dc.subject.MESHNiclosamide / pharmacology-
dc.subject.MESHTemozolomide / pharmacology-
dc.subject.MESHXenograft Model Antitumor Assays-
dc.titleCombined effects of niclosamide and temozolomide against human glioblastoma tumorspheres-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Neurosurgery (신경외과학교실)-
dc.contributor.googleauthorHyeong-Cheol Oh-
dc.contributor.googleauthorJin-Kyoung Shim-
dc.contributor.googleauthorJunseong Park-
dc.contributor.googleauthorJi-Hyun Lee-
dc.contributor.googleauthorRan Joo Choi-
dc.contributor.googleauthorNam Hee Kim-
dc.contributor.googleauthorHyun Sil Kim-
dc.contributor.googleauthorJu Hyung Moon-
dc.contributor.googleauthorEui Hyun Kim-
dc.contributor.googleauthorJong Hee Chang-
dc.contributor.googleauthorJong In Yook-
dc.contributor.googleauthorSeok-Gu Kang-
dc.identifier.doi10.1007/s00432-020-03330-7-
dc.contributor.localIdA00036-
dc.contributor.localIdA00360-
dc.contributor.localIdA00837-
dc.contributor.localIdA01121-
dc.contributor.localIdA01383-
dc.contributor.localIdA02536-
dc.contributor.localIdA03470-
dc.relation.journalcodeJ01283-
dc.identifier.eissn1432-1335-
dc.identifier.pmid32712753-
dc.subject.keywordGlioblastoma-
dc.subject.keywordInvasion-
dc.subject.keywordNiclosamide-
dc.subject.keywordTemozolomide-
dc.subject.keywordTumorsphere-
dc.contributor.alternativeNameKang, Seok Gu-
dc.contributor.affiliatedAuthor강석구-
dc.contributor.affiliatedAuthor김남희-
dc.contributor.affiliatedAuthor김의현-
dc.contributor.affiliatedAuthor김현실-
dc.contributor.affiliatedAuthor문주형-
dc.contributor.affiliatedAuthor육종인-
dc.contributor.affiliatedAuthor장종희-
dc.citation.volume146-
dc.citation.number11-
dc.citation.startPage2817-
dc.citation.endPage2828-
dc.identifier.bibliographicCitationJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, Vol.146(11) : 2817-2828, 2020-11-
Appears in Collections:
2. College of Dentistry (치과대학) > Research Institute (부설연구소) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Neurosurgery (신경외과학교실) > 1. Journal Papers
2. College of Dentistry (치과대학) > Dept. of Oral Pathology (구강병리학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.